ST034307 |
| Catalog No.GC18584 |
ST034307 is an inhibitor of adenylyl cyclase 1 (AC1), a membrane-bound AC, with an IC50 value of 2.3 uM for A23187-stimulated cAMP accumulation in HEK293 cells transfected with AC1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 133406-29-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ST034307 is a potent and selective adenylyl cyclase 1 (AC1) inhibitor, with IC50 of 2.3 μM.
ST034307 reveals selective inhibition of AC1 and potentiates AC8 activity to a nonsignificant small extent. ST034307 potentiates phorbol 12-myristate 13-acetate (PMA)-stimulated cAMP production by AC2. ST034307 significantly inhibits the forskolin- or isoproterenol-stimulated AC1 activity in HEK cells stably expressing AC1. In contrast, ST034307 has no significant effects in the wild-type HEK cells. ST034307 significantly inhibits the Ca2+/calmodulin-stimulated cAMP accumulation in the hippocampal homogenates. ST034307 dose-dependently inhibits both the development and the maintenance of MOR-mediated sensitization of AC1[1].
ST034307 (0.25 μg) causes a significant relief of CFA-induced inflammatory pain in mice. ST034307 exhibits an estimated median effective dose (E50) value for analgesia of 0.28 μg in the mouse pain model[1].
References:
[1]. Brust TF, et al. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci Signal. 2017 Feb 21;10(467).
Cell experiment: | Cell viability assays are conducted with HEK-AC1 cells following plating and compound incubation protocols identical to the procedures described in “cAMP accumulation in cells.” Cell viability is measured as a percentage of vehicle using 2% Triton X-100 as a control. The CellTiter-Glo Luminescent Cell Viability Assay kit from Promega is used to assess cell viability according to the manufacturer’s instructions. Luminescence counts are measured using Synergy 4. |
References: [1]. Brust TF, et al. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci Signal. 2017 Feb 21;10(467). | |
| Cas No. | 133406-29-8 | SDF | |
| Chemical Name | 6-chloro-2-(trichloromethyl)-4H-1-benzopyran-4-one | ||
| Canonical SMILES | O=C1C2=CC(Cl)=CC=C2OC(C(Cl)(Cl)Cl)=C1 | ||
| Formula | C10H4Cl4O2 | M.Wt | 298 |
| Solubility | DMF: 10 mg/ml,DMF:PBS (pH 7.2) (1:4): 0.2 mg/ml,DMSO: 5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3557 mL | 16.7785 mL | 33.557 mL |
| 5 mM | 0.6711 mL | 3.3557 mL | 6.7114 mL |
| 10 mM | 0.3356 mL | 1.6779 mL | 3.3557 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *